Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2113827 | Cancer Letters | 2011 | 9 Pages |
Abstract
The serine/threonine Pim 1 kinase is an oncogene whose expression is deregulated in several human cancers. Overexpression of Pim 1 facilitates cell cycle progression and suppresses apoptosis. Hence pharmacologic inhibitors of Pim 1 are of therapeutic interest for cancer. ETP-45299 is a potent and selective inhibitor of Pim 1 that inhibits the phosphorylation of Bad and 4EBP1 in cells and suppresses the proliferation of several non-solid and solid human tumor cell lines. The combination of the PI3K inhibitor GDC-0941 with ETP-45299 was strongly synergistic in MV-4-11 AML cells, indicating that the combination of selective Pim kinase inhibitors and PI3K inhibitor could have clinical benefit.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Carmen Blanco-Aparicio, Ana María García Collazo, Julen Oyarzabal, Juan F. Leal, María Isabel Albarán, Francisco Ramos Lima, Belén Pequeño, Nuria Ajenjo, Mercedes Becerra, Patricia Alfonso, María Isabel Reymundo, Irene Palacios, Genoveva Mateos,